Date clarification: Cognizant is scheduled to report today, Wednesday, July 29, 2026, before the U.S. market opens, with its earnings call at 8:30 a.m. ET—not tomorrow. This preview uses information available through the July 28 close and is framed as a pre-results note.
Cognizant enters 2Q26 with a relatively clear near-term setup: revenue should be within the guided range, but the market will focus more heavily on the durability of growth, bookings, margin execution, and management’s full-year outlook.
The investment case has two competing forces:
The stock’s recent action underscores the skepticism. CTSH closed at $50.33 on July 28, down about 8.7% from $55.12 on April 28, despite rebounding materially from its late-June low near $39. The bar for a positive reaction is therefore likely not just a modest EPS beat; investors will want confirmation that Cognizant can sustain growth while converting AI-led productivity into margins and new revenue pools.
| Metric | 2Q26 company outlook / market expectation | Why it matters |
|---|---|---|
| Revenue | $5.45B–$5.52B company guide | Implies 3.8%–5.3% reported growth, or 3.2%–4.7% constant-currency growth |
| Revenue consensus | ~$5.49B | Roughly the midpoint of company guidance |
| Adjusted EPS consensus | ~$1.38 | EPS must be viewed alongside Project Leap charges and accelerated buybacks |
| FY26 CC revenue guide | 4.0%–6.5% | The most important forward-looking financial indicator |
| FY26 adjusted operating margin | 16.0%–16.2% | Raised after Project Leap; execution is central to the story |
| FY26 adjusted EPS | $5.63–$5.77 | Represents 7%–9% growth in management’s prior framework |
Management’s 2Q revenue guide includes approximately 150 basis points of contribution from acquisitions, including a partial-quarter contribution from Astreya. That makes the organic-growth discussion especially important: investors will look for evidence that underlying demand—not just M&A and third-party-product revenue—is improving.
In 1Q26, revenue was $5.41B, up 5.8% reported and 3.9% in constant currency. Growth was led by Financial Services, which grew 10.2% in constant currency, while Health Sciences declined 0.9% in constant currency and Products & Resources grew only 1.1%.
For 2Q, the central question is whether the company can deliver toward the upper half of its revenue range despite the cautious demand commentary issued in April.
Areas to monitor: - Financial Services: Whether double-digit constant-currency growth remains intact across banking, insurance, and capital markets. - Health Sciences: Whether healthcare regulatory uncertainty remains a material drag, and whether underlying services growth continues to offset volatility from third-party-product sales. - Products & Resources: Whether trade and supply-chain uncertainty is delaying discretionary transformation work. - CMT: Whether technology-client demand and AI-related engineering work can offset client-specific pressures in communications and media.
A revenue result near the midpoint may be adequate, but the stock is more likely to respond to the quality of that growth—organic services, large-deal ramps, and segment breadth—than to the headline number alone.
Bookings were the standout in 1Q:
Management said large-deal transitions from late 2025 and 1Q26 should begin to contribute more meaningfully during 2Q and 3Q. A second consecutive period of strong bookings—or confirmation that these deals are ramping as planned—would support the case for stronger second-half growth.
The caveat is that management said annual contract value was flat in 1Q as longer-duration large deals increased in the mix and smaller discretionary projects remained soft. Investors should therefore distinguish between an impressive TCV figure and near-term revenue conversion.
Bullish signal: sustained double-digit bookings growth, more large deals, and evidence that deal ramps are translating into revenue.
Bearish signal: a sharp bookings deceleration, weak ACV, or commentary that clients are delaying programs beyond 2026.
Project Leap is the major swing factor for the margin narrative. Cognizant expects the program to generate $200M–$300M of in-year savings during 2026, with a larger full-year benefit in 2027. Management raised full-year adjusted operating-margin guidance to 16.0%–16.2%, or 20–40 bps of year-over-year expansion.
However, the program also carries expected 2026 costs of $230M–$320M, principally severance and related personnel expenses. These costs are excluded from adjusted metrics.
This makes the earnings release especially sensitive to the distinction between:
In 1Q, adjusted operating margin was 15.6%, up 10 bps year over year, but gross margin declined due to higher compensation costs, investments in capacity, and the mix impact of integrated offerings. The 2Q print needs to show that these investment and transition costs are beginning to moderate.
Cognizant is positioning itself as an “AI builder,” emphasizing AI-enabled productivity, enterprise AI integration, and AI-native operations. Management cited more than 5,000 AI engagements exiting 1Q, with nearly 40% of its software-development work AI-assisted.
The company’s strategic argument is that AI will:
The investor concern is that AI-enabled productivity could reduce billable labor hours more quickly than Cognizant can create new, higher-value work. Management’s answer has been to use AI-infused rate cards, token-metering, fixed-price work, and outcome-based commercial models to retain a share of the productivity gain.
For this call, investors should listen for commercial evidence, not just engagement counts:
Cognizant acquired Azure-services specialist 3Cloud at the beginning of 2026 and announced the acquisition of AI-first managed-services provider Astreya for roughly $600M in cash plus a contingent earn-out. Astreya is intended to strengthen data-center, network, digital-workplace, and AI-infrastructure capabilities.
In May, Cognizant also:
This creates an important 2Q cash-flow and balance-sheet checklist. Investors should assess:
Buybacks can meaningfully support EPS, but investors will want to see that capital returns do not compromise Cognizant’s ability to invest in AI capabilities and execute acquisitions.
A constructive setup would include:
The main downside risks are:
CTSH’s 2Q26 report is primarily a test of whether Cognizant can turn strong bookings, acquisitions, and AI positioning into durable organic growth and expanding margins. The company has credible catalysts: Financial Services momentum, a large-deal pipeline, M&A contribution, Project Leap savings, and substantial buyback support.
But the market remains unconvinced that the company can fully offset uneven discretionary demand and AI-related pricing risk. Accordingly, guidance confidence, bookings quality, organic-growth composition, and the credibility of Project Leap savings should matter more than a narrow quarterly EPS beat or miss.